Induction with Mitomycin C, Doxorubicin, Cisplatin And
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
August 2019: Additions and Deletions to the Drug Product List
Prescription and Over-the-Counter Drug Product List 39TH EDITION Cumulative Supplement Number 08 : August 2019 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE TABLET;ORAL APADAZ >D> + KVK TECH INC 325MG;EQ 8.16MG BASE N 208653 003 Jan 04, 2019 Aug CHRS >A> +! 325MG;EQ 8.16MG BASE N 208653 003 Jan 04, 2019 Aug CHRS ACETAMINOPHEN; CODEINE PHOSPHATE TABLET;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >A> AA ELITE LABS INC 300MG;15MG A 212418 001 Sep 10, 2019 Aug NEWA >A> AA 300MG;30MG A 212418 002 Sep 10, 2019 Aug NEWA >A> AA 300MG;60MG A 212418 003 Sep 10, 2019 Aug NEWA ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE TABLET;ORAL OXYCODONE AND ACETAMINOPHEN >D> AA CHEMO RESEARCH SL 325MG;5MG A 207574 001 Dec 13, 2016 Aug CAHN >A> AA HALO PHARM CANADA 325MG;5MG A 207834 001 Aug 15, 2019 Aug NEWA >A> AA 325MG;7.5MG A 207834 002 Aug 15, 2019 Aug NEWA >A> AA 325MG;10MG A 207834 003 Aug 15, 2019 Aug NEWA >A> AA XIROMED 325MG;5MG A 207574 001 Dec 13, 2016 Aug CAHN ACYCLOVIR CAPSULE;ORAL ACYCLOVIR >A> AB CADILA 200MG A 204313 001 Mar 25, 2016 Aug CAHN >D> AB ZYDUS PHARMS 200MG A 204313 001 Mar 25, 2016 Aug CAHN >D> OINTMENT;OPHTHALMIC >D> AVACLYR >D> +! FERA PHARMS LLC 3% N 202408 001 Mar 29, 2019 Aug DISC >A> + @ 3% N 202408 001 Mar 29, 2019 Aug DISC OINTMENT;TOPICAL ACYCLOVIR >A> AB APOTEX INC 5% A 210774 001 Sep 06, 2019 Aug NEWA >D> AB PERRIGO UK FINCO 5% A 205659 001 Feb 20, 2019 Aug DISC >A> @ 5% A 205659 001 Feb 20, 2019 Aug DISC ALBENDAZOLE TABLET;ORAL ALBENDAZOLE >A> AB STRIDES PHARMA 200MG A 210011 -
The Limitations of DNA Interstrand Cross-Link Repair in Escherichia Coli
Portland State University PDXScholar Dissertations and Theses Dissertations and Theses 7-12-2018 The Limitations of DNA Interstrand Cross-link Repair in Escherichia coli Jessica Michelle Cole Portland State University Follow this and additional works at: https://pdxscholar.library.pdx.edu/open_access_etds Part of the Biology Commons Let us know how access to this document benefits ou.y Recommended Citation Cole, Jessica Michelle, "The Limitations of DNA Interstrand Cross-link Repair in Escherichia coli" (2018). Dissertations and Theses. Paper 4489. https://doi.org/10.15760/etd.6373 This Thesis is brought to you for free and open access. It has been accepted for inclusion in Dissertations and Theses by an authorized administrator of PDXScholar. Please contact us if we can make this document more accessible: [email protected]. The Limitations of DNA Interstrand Cross-link Repair in Escherichia coli by Jessica Michelle Cole A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in Biology Thesis Committee: Justin Courcelle, Chair Jeffrey Singer Rahul Raghavan Portland State University 2018 i Abstract DNA interstrand cross-links are a form of genomic damage that cause a block to replication and transcription of DNA in cells and cause lethality if unrepaired. Chemical agents that induce cross-links are particularly effective at inactivating rapidly dividing cells and, because of this, have been used to treat hyperproliferative skin disorders such as psoriasis as well as a variety of cancers. However, evidence for the removal of cross- links from DNA as well as resistance to cross-link-based chemotherapy suggests the existence of a cellular repair mechanism. -
Arsenic Trioxide Is Highly Cytotoxic to Small Cell Lung Carcinoma Cells
160 Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells 1 1 Helen M. Pettersson, Alexander Pietras, effect of As2O3 on SCLC growth, as suggested by an Matilda Munksgaard Persson,1 Jenny Karlsson,1 increase in neuroendocrine markers in cultured cells. [Mol Leif Johansson,2 Maria C. Shoshan,3 Cancer Ther 2009;8(1):160–70] and Sven Pa˚hlman1 1Center for Molecular Pathology, CREATE Health and 2Division of Introduction Pathology, Department of Laboratory Medicine, Lund University, 3 Lung cancer is the most frequent cause of cancer deaths University Hospital MAS, Malmo¨, Sweden; and Department of f Oncology-Pathology, Cancer Center Karolinska, Karolinska worldwide and results in 1 million deaths each year (1). Institute and Hospital, Stockholm, Sweden Despite novel treatment strategies, the 5-year survival rate of lung cancer patients is only f15%. Small cell lung carcinoma (SCLC) accounts for 15% to 20% of all lung Abstract cancers diagnosed and is a very aggressive malignancy Small cell lung carcinoma (SCLC) is an extremely with early metastatic spread (2). Despite an initially high aggressive form of cancer and current treatment protocols rate of response to chemotherapy, which currently com- are insufficient. SCLC have neuroendocrine characteristics bines a platinum-based drug with another cytotoxic drug and show phenotypical similarities to the childhood tumor (3, 4), relapses occur in the absolute majority of SCLC neuroblastoma. As multidrug-resistant neuroblastoma patients. At relapse, the efficacy of further chemotherapy is cells are highly sensitive to arsenic trioxide (As2O3) poor and the need for alternative treatments is obvious. in vitro and in vivo, we here studied the cytotoxic effects Arsenic-containing compounds have been used in tradi- of As2O3 on SCLC cells. -
5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells
Article Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells Maria Pereira-Oliveira, Ana Reis-Mendes, Félix Carvalho, Fernando Remião, Maria de Lourdes Bastos and Vera Marisa Costa * UCIBIO, REQUIMTE, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal; [email protected] (M.P.-O.); [email protected] (A.R.-M.); [email protected] (F.C.); [email protected] (F.R.); [email protected] (M.L.B.) * Correspondence: [email protected] Received: 4 October 2018; Accepted: 3 January 2019; Published: 10 January 2019 Abstract: Currently, a common therapeutic approach in cancer treatment encompasses a drug combination to attain an overall better efficacy. Unfortunately, it leads to a higher incidence of severe side effects, namely cardiotoxicity. This work aimed to assess the cytotoxicity of doxorubicin (DOX, also known as Adriamycin), 5-fluorouracil (5-FU), cyclophosphamide (CYA), and their combination (5-Fluorouracil + Adriamycin + Cyclophosphamide, FAC) in H9c2 cardiac cells, for a better understanding of the contribution of each drug to FAC-induced cardiotoxicity. Differentiated H9c2 cells were exposed to pharmacological relevant concentrations of DOX (0.13–5 μM), 5-FU (0.13–5 μM), CYA (0.13–5 μM) for 24 or 48 h. Cells were also exposed to FAC mixtures (0.2, 1 or 5 μM of each drug and 50 μM 5-FU + 1 μM DOX + 50 μM CYA). DOX was the most cytotoxic drug, followed by 5-FU and lastly CYA in both cytotoxicity assays (reduction of 3-(4,5-dimethylthiazol-2- yl)-2,5-diphenyl tetrazolium bromide (MTT) and neutral red (NR) uptake). -
Characteristics of Doxorubicin‑Selected Multidrug‑Resistant Human Leukemia HL‑60 Cells with Tolerance to Arsenic Trioxide and Contribution of Leukemia Stem Cells
ONCOLOGY LETTERS 15: 1255-1262, 2018 Characteristics of doxorubicin‑selected multidrug‑resistant human leukemia HL‑60 cells with tolerance to arsenic trioxide and contribution of leukemia stem cells JING CHEN, HULAI WEI, JIE CHENG, BEI XIE, BEI WANG, JUAN YI, BAOYING TIAN, ZHUAN LIU, FEIFEI WANG and ZHEWEN ZHANG Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu 730000, P.R. China Received December 29, 2015; Accepted June 9, 2017 DOI: 10.3892/ol.2017.7353 Abstract. The present study selected and characterized resistance (MDR) frequently induces therapy failure or tumor a multidrug-resistant HL-60 human acute promyelocytic recurrence (1-3). MDR involves various mechanisms including, leukemia cell line, HL-60/RS, by exposure to stepwise adenosine triphosphate-binding cassette (ABC) transporters, incremental doses of doxorubicin. The drug-resistant P-glycoprotein (P-gp), multidrug-resistance-related protein HL-60/RS cells exhibited 85.68-fold resistance to doxoru- (MRP) and breast-cancer-resistance protein (BCRP) overex- bicin and were cross-resistant to other chemotherapeutics, pression, which function to efflux certain molecules out of including cisplatin, daunorubicin, cytarabine, vincristine the cells (4-8). In addition, mechanisms of acquired MDR and etoposide. The cells over-expressed the transporters in leukemia also include abnormal drug metabolism and the P-glycoprotein, multidrug-resistance-related protein 1 presence of leukemia stem cells (LSC). LSCs are particu- and breast-cancer-resistance protein, encoded by the larly of interest and considered to serve an important role adenosine triphosphate-binding cassette (ABC)B1, ABCC1 in leukemia resistance and relapse (4). -
Sex-Specific Effects of Cytotoxic Chemotherapy Agents
www.impactaging.com AGING, April 2016, Vol 8 No 4 Research Paper Sex‐specific effects of cytotoxic chemotherapy agents cyclophospha‐ mide and mitomycin C on gene expression, oxidative DNA damage, and epigenetic alterations in the prefrontal cortex and hippocampus – an aging connection 1 2 2 2 Anna Kovalchuk , Rocio Rodriguez‐Juarez , Yaroslav Ilnytskyy , Boseon Byeon , Svitlana 3,4 4 3 1,5,6 2,5 Shpyleva , Stepan Melnyk , Igor Pogribny , Bryan Kolb, , and Olga Kovalchuk 1 Department of Neuroscience, University of Lethbridge, Lethbridge, AB, T1K3M4, Canada 2 Department of Biological Sciences, University of Lethbridge, Lethbridge, AB, T1K3M4, Canada 3 Division of Biochemical Toxicology, Food and Drug Administration National Center for Toxicological Research, Jefferson, AR 72079, USA 4Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72202, USA 5 Alberta Epigenetics Network, Calgary, AB, T2L 2A6, Canada 6 Canadian Institute for Advanced Research, Toronto, ON, M5G 1Z8, Canada Key words: chemotherapy, chemo brain, epigenetics, DNA methylation, DNA hydroxymethylation, oxidative stress, transcriptome, aging Received: 01/08/16; Accepted: 01/30/1 6; Published: 03/30/16 Corresponden ce to: Bryan Kolb, PhD; Olga Kovalchuk, PhD; E‐mail: [email protected]; [email protected] Copyright: Kovalchuk et al. This is an open‐access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Abstract: Recent research shows that chemotherapy agents can be more toxic to healthy brain cells than to the target cancer cells. They cause a range of side effects, including memory loss and cognitive dysfunction that can persist long after the completion of treatment. -
Intravesical Administration of Therapeutic Medication for the Treatment of Bladder Cancer Jointly Developed with the Society of Urologic Nurses and Associates (SUNA)
Intravesical Administration of Therapeutic Medication for the Treatment of Bladder Cancer Jointly developed with the Society of Urologic Nurses and Associates (SUNA) Revised: June 2020 Workgroup Members: AUA: Roxy Baumgartner, RN, APN-BC; Sam Chang, MD; Susan Flick, CNP; Howard Goldman, MD, FACS; Jim Kovarik, MS, PA-C; Yair Lotan, MD; Elspeth McDougall, MD, FRCSC, MHPE; Arthur Sagalowsky, MD; Edouard Trabulsi, MD SUNA: Debbie Hensley, RN; Christy Krieg, MSN, CUNP; Leanne Schimke, MSN, CUNP I. Statement of Purpose: To define the performance guidance surrounding the instillation of intravesical cytotoxic, immunotherapeutic, and/or therapeutic drugs via sterile technique catheterization for patients with non-muscle invasive bladder cancer (NMIBC, urothelial carcinoma). II. Population: Adult Urology III. Definition: Intravesical therapy involves instillation of a therapeutic agent directly into the bladder via insertion of a urethral catheter. IV. Indications: For administration of medication directly into the bladder via catheterization utilizing sterile technique for NMIBC treatment. V. Guidelines and Principles: Health care personnel (MD, NP, PA, RN, LPN, or MA) performing intravesical therapy must be educated, demonstrate competency, and understand the implications of non-muscle invasive bladder cancer. (Scope of practice for health care personnel listed may vary based on state or institution). This should include associated health and safety issues regarding handling of cytotoxic, and immunotherapeutic agents; and documented competency of safe practical skills. At a minimum, each institution or office practice setting should implement an established, annual competency program to review safety work practices and guidelines regarding storage, receiving, handling/ transportation, administration, disposal, and handling a spill of hazardous drugs. (Mellinger, 2010) VI. -
Combination of Oxoplatin with Other FDA-Approved Oncology Drugs
International Journal of Molecular Sciences Article Theoretical Prediction of Dual-Potency Anti-Tumor Agents: Combination of Oxoplatin with Other FDA-Approved Oncology Drugs José Pedro Cerón-Carrasco Reconocimiento y Encapsulación Molecular, Universidad Católica San Antonio de Murcia Campus los Jerónimos, 30107 Murcia, Spain; [email protected] Received: 16 April 2020; Accepted: 2 July 2020; Published: 3 July 2020 Abstract: Although Pt(II)-based drugs are widely used to treat cancer, very few molecules have been approved for routine use in chemotherapy due to their side-effects on healthy tissues. A new approach to reducing the toxicity of these drugs is generating a prodrug by increasing the oxidation state of the metallic center to Pt(IV), a less reactive form that is only activated once it enters a cell. We used theoretical tools to combine the parent Pt(IV) prodrug, oxoplatin, with the most recent FDA-approved anti-cancer drug set published by the National Institute of Health (NIH). The only prerequisite imposed for the latter was the presence of one carboxylic group in the structure, a chemical feature that ensures a link to the coordination sphere via a simple esterification procedure. Our calculations led to a series of bifunctional prodrugs ranked according to their relative stabilities and activation profiles. Of all the designed molecules, the combination of oxoplatin with aminolevulinic acid as the bioactive ligand emerged as the most promising strategy by which to design enhanced dual-potency oncology drugs. Keywords: cancer; drug design; organometallics; platinum-based drugs; bifunctional compounds; theoretical tools 1. Introduction The unexpected discovery of the bioactivity of Pt salts by Rosenberg about 60 years ago opened the door to a new type of cancer treatment: chemotherapy with transition metals [1]. -
Small Cell Lung Cancer (SCLC) Algorithm
Small Cell Lung Cancer (SCLC) Page 1 of 8 Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women. Note: Consider Clinical Trials as treatment options for eligible patients. INITIAL EVALUATION STAGE ● Pathology consistent with SCLC Limited Stage ● History and physical AJCC Stage I-III2, see Page 2 ● Laboratory studies to include hematological and full chemistry panels ● FDG PET/CT and CT chest with IV contrast ○ If FDG PET/CT not available: nuclear medicine bone scan and CT chest, abdomen, and pelvis with IV contrast ● MRI brain with IV contrast (preferred) or CT head with IV contrast ● MRI spine, lumbar puncture and bone marrow aspirate/biopsy as indicated ● Pulmonary function tests 1 Extensive Stage ● Lifestyle risk assessment AJCC Stage IV3, see Page 3 ● Molecular profiling (for never smokers) AJCC = American Joint Committee on Cancer 1 See Physical Activity, Nutrition, and Tobacco Cessation algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice 2 Limited stage: Stage I-III (T any, N any, M0) per AJCC 8th edition or disease confined to the ipsilateral hemithorax -
Cisplatin and Etoposide (Lung)
Cisplatin and Etoposide (lung) _____________________________________________________________________________________________ Indication First line chemotherapy for patients with small cell lung cancer (SCLC), who have a good performance status (WHO PS 0-2). Concomitant radiotherapy may start with cycle 2. ICD-10 codes Codes pre-fixed with C34 Regimen details Day Drug Dose Route 1 Cisplatin 75-80mg/m² IV infusion 1 Etoposide 100mg/m² IV infusion 2 and 3 or Etoposide 100mg/m² IV infusion 2 and 3 Etoposide 200mg/m2 PO Cycle frequency 21 days Number of cycles 4 - 6 cycles (usually 4) Administration Cisplatin is administered in 500mL sodium chloride 0.9% over 60 minutes following the pre and post hydration protocol below. Infusion Fluid & Additives Volume Infusion Time Sodium Chloride 0.9% 1000mL 1 hour Mannitol 20% 200mL 30 minutes OR Mannitol 10% 400mL 30 minutes Ensure urine output > 100mL / hour prior to giving cisplatin. Give a single dose of furosemide 20mg iv if necessary. Cisplatin 500mL 1 hour Sodium Chloride 0.9% + 2g MgSO4 + 1000mL 2 hours 20mmol KCl TOTAL 2700mL or 2900mL 4 hours 30 minutes Note: Patients with magnesium or potassium below the normal range should have 2g MgSO4 and 20mmol KCl added to the pre-hydration bag and the duration of the infusion increased to 2 hours. All patients must be advised to drink at least 2 litres of fluid over the following 24 hours. IV etoposide is administered in 1000mL sodium chloride 0.9% and infused over a minimum of 1 hour. Version 1 Review date June 2018 Page 1 of 4 Oral etoposide is available as 50mg and 100mg capsules. -
Cyclophosphamide-Doxorubicin Ver
Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-DOXORUBICIN Regimen Breast Cancer – Cyclophosphamide-Doxorubicin Indication Primary systemic (neoadjuvant) therapy of breast cancer Adjuvant therapy of high risk (greater than 5%) node negative breast cancer WHO Performance status 0, 1, 2 Toxicity Drug Adverse Effect Cyclophosphamide Dysuria, haemorrhagic cystitis, taste disturbances Doxorubicin Cardio toxicity, urinary discolourisation (red) The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details. Monitoring Regimen FBC, U&E’s and LFT’s prior to each cycle. Ensure adequate cardiac function before starting treatment with doxorubicin. Baseline LVEF should be measured, particularly in patients with a history of cardiac problems or in the elderly. Dose Modifications The dose modifications listed are for haematological, liver and renal function only. Dose adjustments may be necessary for other toxicities as well. In principle all dose reductions due to adverse drug reactions should not be re- escalated in subsequent cycles without consultant approval. It is also a general rule for chemotherapy that if a third dose reduction is necessary treatment should be stopped. Version 1.1 (Aug 2014) Page 1 of 6 Breast – Cyclophosphamide-Doxorubicin Please discuss all dose reductions / delays with the relevant consultant before prescribing if appropriate. The approach may be different depending on the clinical circumstances. The following is a general guide only. Haematological Prior to prescribing the following treatment criteria must be met on day 1 of treatment. Criteria Eligible Level Neutrophil equal to or more than 1x109/L Platelets equal to or more than 100x109/L Consider blood transfusion if patient symptomatic of anaemia or has a haemoglobin of less than 8g/dL If counts on day one are below these criteria for neutrophil and/or platelets then delay treatment for seven days. -
For Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline
ANTICANCER RESEARCH 36: 419-426 (2016) Mitomycin C and Capecitabine (MiX Trial) for Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline KATRIN ALMSTEDT1, PETER A. FASCHING1, ANTON SCHARL2, CLAUDIA RAUH1, BRIGITTE RACK3, ALEXANDER HEIN1, CAROLIN C. HACK1, CHRISTIAN M. BAYER1, SEBASTIAN M. JUD1, MICHAEL G. SCHRAUDER1, MATTHIAS W. BECKMANN1 and MICHAEL P. LUX1 1Department of Obstetrics and Gynaecology, University of Erlangen, Erlangen, Germany; 2Department of Gynecology and Obstetrics, St. Marien Hospital, Amberg, Germany; 3Department of Gynecology and Obstetrics, Ludwig Maximilian University, Munich, Germany Abstract. Background/Aim: The aim of this single-arm, (MBC) is still a challenge. The majority of patients with prospective, multicenter phase II trial (MiX) was to increase breast cancer receive an anthracycline-based regimen as first treatment options for women with metastatic breast cancer chemotherapy, in an adjuvant, neoadjuvant, or metastatic pretreated with anthracycline and taxane by evaluation of the setting. The development of drug resistance and impairment efficacy and toxicity of the combination of mitomycin C and of organ functions limits the choice of further cytotoxic capecitabine. Patients and Methods: From 03/2004 to drugs in the metastatic situation. Although many patients are 06/2007, a total of 39 patients were recruited and received willing to receive further anticancer therapy to counteract mitomycin C in combination with capecitabine. The primary tumor growth, they often request a less toxic but still end-point was to determinate the tumor response according effective therapy. At present taxanes (e.g. paclitaxel, to Response Evaluation Criteria in Solid Tumors and the rate docetaxel, nab-paclitaxel), eribulin, vinorelbine, 5- of toxicities (safety).